Omnia SanaPlant Comparison
Mugwort vs Perforate St John’s-wort
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Mugwort and Perforate St John’s-wort: they share 6 indicated uses (arthritis / joint pain, infection (general), inflammation (general), …); 3 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Mugwort | Perforate St John’s-wort | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Infection (general) | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Insomnia / sleeplessness | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
| Wounds | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Multiple undescribed and known sesquiterpenoids and triterpenoids isolated from the leaves, several with anti-inflammatory activity.
Volatile oil containing thujone and other monoterpenes; thujone content is the basis of the caution on prolonged internal use.
Antioxidant and anti-inflammatory flavonoid and coumarin constituents.
Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.
Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.
Antioxidant flavonoids contributing to overall activity.
Pharmacological Actions
Artemisia vulgaris (mugwort) extracts inhibit BCR/ABL and induce apoptosis, ferroptosis and necroptosis in chronic myeloid leukaemia and breast cancer cells (preclinical).
Traditional & Indicated Uses
inferred from anti-inflammatory action
Artemisia vulgaris (mugwort) extracts inhibit BCR/ABL and induce apoptosis in chronic myeloid leukaemia cells (including imatinib-resistant), and trigger tumour-selective ferroptosis/necroptosis in breast cancer and leukaemia cells via lysosomal Ca2+ signalling (preclinical).
inferred from digestive action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from sedative action
inferred from antispasmodic action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from antiviral action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Contains thujone; avoid high doses or prolonged use. Contraindicated in pregnancy (uterine stimulant and abortifacient). May cause allergic reactions in individuals sensitive to the Asteraceae family. Avoid in epilepsy. Not recommended for children.
Duke (2002) rates mugwort as + (use with caution) and notes abortifacient (score 1), emmenagogue, aperitif (score 1), and insecticide activities. Duke clearly flags mugwort as contraindicated in pregnancy due to well-documented abortifacient and uterotonic properties. Traditional use has been as a digestive bitter, and the plant contains volatile oils, sesquiterpene lactones, and flavonoids. Duke notes that the plant may cause allergic reactions in individuals sensitive to Asteraceae and warns against long-term use due to potential neurotoxicity from thujone-containing essential oil (Duke, 2002).
Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.
Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).
External Ids
Botanical Description
Tall, aromatic perennial herb with deeply lobed, dark green leaves that are distinctively silvery-white and woolly beneath. Small, dull reddish-brown to yellowish flower heads are borne in dense, branched, leafy spikes. The reddish-brown, ridged stems and the leaf's contrasting silver underside are characteristic field marks.[3]
Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]
Habitat
A common plant of waste ground, roadsides, hedgerows and riverbanks; native to Europe, Asia and North Africa and widely naturalised in North America.[3]
Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]
Harvesting
The flowering aerial parts (leaf and stem) are cut in summer as flowering begins and dried in a warm, shaded, airy place; the root can be dug in autumn.[3]
The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]
Traditional Uses
Mugwort is a widely used traditional bitter digestive tonic and calming nervine, and has a long reputation as an emmenagogue for menstrual complaints (reflected in its traditional use to bring on delayed menstruation, which is also why it is contraindicated in pregnancy). It has also been burned as 'moxa' in East Asian moxibustion and used as an insect repellent ('sailor's tobacco').[3]
St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]
Preparations
Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.
Dosage
Health Canada's NNHPD monograph gives 0.2-2.4 g of dried herb top, 3 times per day, for adults 18 years and older, with infusion and decoction among the accepted methods of preparation. Educational reference only, not a prescription.
Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.
References
Drug Class Interactions
Lookalikes Review
Dangerous Lookalikes
Not documented
Pairings
Not documented
St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]
St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]
St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]
St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]
References & Sources
- Liu, T., Chen, X., Hu, Y., Li, M., Wu, Y. et al (2022) 'Sesquiterpenoids and triterpenoids with anti-inflammatory effects from Artemisia vulgaris L', Phytochemistry, 204, pp. 113428. doi:10.1016/j.phytochem.2022.113428 Preclinical
https://doi.org/10.1016/j.phytochem.2022.113428 - Trinh, P.T.N., Truc, N.C., Danh, T.T., Trang, N.T.T., Le Hang, D.T. et al (2024) 'A study on the antioxidant, anti-inflammatory, and xanthine oxidase inhibitory activity of the Artemisia vulgaris L. extract and its fractions', Journal of Ethnopharmacology, 334, pp. 118519. doi:10.1016/j.jep.2024.118519 Preclinical
https://doi.org/10.1016/j.jep.2024.118519 - Abiri, R., Silva, A.L.M., de Mesquita, L.S.S., de Mesquita, J.W.C., Atabaki, N. et al (2018) 'Towards a better understanding of Artemisia vulgaris: Botany, phytochemistry, pharmacological and biotechnological potential', Food Research International, 109, pp. 403-415. doi:10.1016/j.foodres.2018.03.072 Traditional / reference
https://doi.org/10.1016/j.foodres.2018.03.072 - Ekiert, H., Pajor, J., Klin, P., Rzepiela, A., Slesak, H. and Szopa, A (2020) 'Significance of Artemisia vulgaris L. (Common Mugwort) in the History of Medicine and Its Possible Contemporary Applications Substantiated by Phytochemical and Pharmacological Studies', Molecules, 25(19), pp. 4415. doi:10.3390/molecules25194415 Meta-analysis / review
https://doi.org/10.3390/molecules25194415 - Soon, L., Ng, P.Q., Chellian, J., Madheswaran, T., Panneerselvam, J., Gupta, G., Nammi, S., Hansbro, N.G., Hsu, A., Dureja, H., Mehta, M., Satija, S., Hansbro, P.M., Collet, T. and Chellappan, D.K (2019) 'Therapeutic potential of Artemisia vulgaris: An insight into underlying immunological mechanisms', Journal of Environmental Pathology, Toxicology and Oncology, 38(3), pp. 205-216. doi:10.1615/JEnvironPatholToxicolOncol.2019029397 Meta-analysis / review
https://doi.org/10.1615/JEnvironPatholToxicolOncol.2019029397 - Xiao, J., Liu, P., Hu, Y., Liu, T., Guo, Y., Sun, P., Zheng, J., Ren, Z. and Wang, Y (2023) 'Antiviral activities of Artemisia vulgaris L. extract against herpes simplex virus', Chinese Medicine, 18(1), pp. 21. doi:10.1186/s13020-023-00711-1 Preclinical
https://doi.org/10.1186/s13020-023-00711-1 - Singh, N.B., Devi, M.L., Biona, T., Sharma, N., Das, S., Chakravorty, J., Mukherjee, P.K. and Rajashekar, Y (2023) 'Phytochemical Composition and Antimicrobial Activity of Essential Oil from the Leaves of Artemisia vulgaris L', Molecules, 28(5), pp. 2279. doi:10.3390/molecules28052279 Preclinical
https://doi.org/10.3390/molecules28052279 - Judzentiene, A. and Budiene, J (2018) 'Chemical Polymorphism of Essential Oils of Artemisia vulgaris Growing Wild in Lithuania', Chemistry & Biodiversity, 15(2), pp. e1700257. doi:10.1002/cbdv.201700257 Preclinical
https://doi.org/10.1002/cbdv.201700257 - Hanh, T.T.H., Vinh, L.B., Cuong, N.X. and Quang, T.H (2022) 'Two new eudesmane sesquiterpene glucosides from the aerial parts of Artemisia vulgaris', Natural Product Research, 37(9), pp. 1544-1549. doi:10.1080/14786419.2022.2025591 Preclinical
https://doi.org/10.1080/14786419.2022.2025591 - Zamarioli, L.D.S., Santos, M.R.M., Erustes, A.G., Meccatti, V.M., Pereira, T.C., Smaili, S.S., Marcucci, M.C., Oliveira, C.R., Pereira, G.J.S. and Bincoletto, C (2023) 'Artemisia vulgaris Induces Tumor-Selective Ferroptosis and Necroptosis via Lysosomal Ca2+ Signaling', Chinese Journal of Integrative Medicine, 30(6), pp. 525-533. doi:10.1007/s11655-023-3712-2 Preclinical
https://doi.org/10.1007/s11655-023-3712-2 - Chi, H.T. and Ly, B.T.K (2022) 'Artemisia vulgaris inhibits BCR/ABL and promotes apoptosis in chronic myeloid leukemia cells', Biomedical Reports, 17(6), pp. 92. doi:10.3892/br.2022.1575 Preclinical
https://doi.org/10.3892/br.2022.1575 - Tiwari, R.K., Ahmad, A., Khan, A.F., Al-Keridis, L.A., Saeed, M., Alshammari, N., Alabdallah, N.M., Ansari, I.A. and Mujeeb, F (2023) 'Ethanolic Extract of Artemisia vulgaris Leaf Promotes Apoptotic Cell Death in Non-Small-Cell Lung Carcinoma A549 Cells through Inhibition of the Wnt Signaling Pathway', Metabolites, 13(4), pp. 480. doi:10.3390/metabo13040480 Preclinical
https://doi.org/10.3390/metabo13040480 - Health Canada, Natural and Non-prescription Health Products Directorate (2026) 'Natural Health Product Monograph: Mugwort - Artemisia vulgaris'. Available at: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_mugwort_english.pdf Traditional / reference
https://webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_mugwort_english.pdf - Becker, H (1986) 'Botany of European Artemisia species', pp. 1--24. Traditional / reference
https://scholar.google.com/scholar?q=Botany%20of%20European%20Artemisia%20species - Grieve, M (1931) 'A Modern Herbal'. Traditional / reference
https://scholar.google.com/scholar?q=A%20Modern%20Herbal - Kung, H.J. and Ko, W.C (2002) 'Pharmacological studies of Artemisia vulgaris', 13(2), pp. 99--108. Traditional / reference
https://scholar.google.com/scholar?q=Pharmacological%20studies%20of%20Artemisia%20vulgaris - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003 - Totally Wild UK 'Mugwort (Artemisia vulgaris) Identification'. Available at: https://totallywilduk.co.uk/2021/04/13/identify-mugwort/ Traditional / reference
https://totallywilduk.co.uk/2021/04/13/identify-mugwort/ - Stetzenbach, M. and Schnorbus, B. and Sagoschen, I. and Bleser, W. and Legner, D. and Sturer, A (2017) 'Acute Monkshood Intoxication Requiring Acute Resuscitation', Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie, 52(9), pp. 641-644. doi:10.1055/s-0043-106283 Clinical study
https://doi.org/10.1055/s-0043-106283
- Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
https://doi.org/10.1016/j.jad.2016.12.048 - Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
https://doi.org/10.1007/s00210-022-02229-z - Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
https://doi.org/10.1016/S0140-6736(99)06457-0 - Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
https://doi.org/10.22038/IJBMS.2022.65112.14338 - Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
https://doi.org/10.1016/j.phymed.2024.155847 - Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
https://doi.org/10.3389/fpls.2016.01004 - Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
https://doi.org/10.1002/ptr.5050 - Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
https://doi.org/10.1016/j.jep.2010.07.034 - Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
https://doi.org/10.1016/j.lfs.2004.04.005 - Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
https://doi.org/10.3109/13697137.2013.861814 - Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
https://doi.org/10.2165/00003088-200645050-00002 - Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
https://doi.org/10.1055/s-2001-15467 - Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
https://doi.org/10.1038/sj.mp.4000557 - Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
https://doi.org/10.2174/1568026033392589 - Linde, K. et al (2008) 'St John'. Traditional / reference
https://scholar.google.com/scholar?q=St%20John - Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
https://doi.org/10.1177/0269881104042632 - Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
https://doi.org/10.2165/11317010-000000000-00000 - Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
https://doi.org/10.1208/s12248-009-9146-8 - Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
https://doi.org/10.1111/bph.14936 - Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
https://doi.org/10.1016/S0140-6736(99)05712-8 - Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
https://doi.org/10.1345/aph.10088 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
https://doi.org/10.1046/j.1365-2125.2003.02005.x - Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
https://doi.org/10.1053/cp.1999.v66.a101944 - Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
https://doi.org/10.1093/jnci/94.16.1247 - Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
https://doi.org/10.1592/phco.24.16.1508.50958 - Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
https://doi.org/10.5414/cpp42139 - Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
https://doi.org/10.3390/ph19030399
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.